Century Therapeutics
Most recent annual filing: 2026-03-15
- CNTY-308 trial start2026CNTY-308 trial start, 2026, routine
- CNTY-813 IND filing4Q 2026CNTY-813 IND filing, 4Q 2026, material
- CNTY-813 topline2H 2027CNTY-813 topline, 2H 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
CNTY-308
CNTY-101
Technology platforms
Allo-Evasion
Proprietary iPSC engineering technology designed to enable allogeneic cell products to evade host immune recognition and rejection, enabling repeat dosing and persistence without chronic immunosuppression. Applicable to NK cell, T cell, and beta islet programs for autoimmune diseases and cancer.
Allo-Evasion 5.0
Immune evasion engineering technology applied to iPSC-derived cell therapies; used in CNTY-813 islet cell replacement program for type 1 diabetes to reduce or eliminate need for chronic immunosuppression following transplantation
Biotech Distilled coverage (3)
- 2026-08-13 UPDATE: Century Therapeutics (IPSC) - The FDA Said Yes to the Homework 🔒 Paid
- 2026-06-08 UPDATE: Century Therapeutics (IPSC) - The Humanized Mouse Passes the Test
- 2026-03-31 Century Therapeutics (IPSC) - Scientific Deep Dive for Allo-Evasion™ and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.